Exclusive: Can Wright Medical Group Inc’s Tomorrow Be Different? The Stock Increases Again

Exclusive: Can Wright Medical Group Inc's Tomorrow Be Different? The Stock Increases Again

The stock of Wright Medical Group Inc (NASDAQ:WMGI) is a huge mover today! About 546,915 shares traded hands. Wright Medical Group Inc (NASDAQ:WMGI) has risen 35.93% since March 7, 2016 and is uptrending. It has outperformed by 28.34% the S&P500.
The move comes after 9 months positive chart setup for the $1.31B company. It was reported on Oct, 10 by Barchart.com. We have $42.08 PT which if reached, will make NASDAQ:WMGI worth $890.80M more.

Analysts await Wright Medical Group Inc (NASDAQ:WMGI) to report earnings on November, 2 after the close. They expect $-0.20 EPS, up 60.78% or $0.31 from last year’s $-0.51 per share. After $-0.18 actual EPS reported by Wright Medical Group Inc for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.

Wright Medical Group Inc (NASDAQ:WMGI) Ratings Coverage

Out of 14 analysts covering Wright Medical Group (NASDAQ:WMGI), 12 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 86% are positive. Wright Medical Group has been the topic of 17 analyst reports since August 20, 2015 according to StockzIntelligence Inc. Northland Capital maintained the shares of WMGI in a report on Wednesday, September 2 with “Buy” rating. The stock of Wright Medical Group Inc (NASDAQ:WMGI) earned “Buy” rating by Jefferies on Monday, November 30. The rating was maintained by Oppenheimer with “Perform” on Monday, November 30. Guggenheim initiated the shares of WMGI in a report on Thursday, June 9 with “Buy” rating. Needham upgraded the shares of WMGI in a report on Monday, February 22 to “Buy” rating. UBS initiated the shares of WMGI in a report on Tuesday, September 22 with “Buy” rating. The company was maintained on Sunday, September 6 by William Blair. The firm has “Buy” rating by Brean Capital given on Thursday, September 3. RBC Capital Markets maintained the shares of WMGI in a report on Tuesday, November 10 with “Outperform” rating. The rating was maintained by Needham with “Hold” on Thursday, September 3.

According to Zacks Investment Research, “Wright Medical Group N.V. is a medical device company which focused on providing extremity and biologic solutions. The company’s surgical solutions for the upper extremity consist of shoulder, elbow, wrist and hand, lower extremity consists of foot and ankle as well as biologics markets. Wright Medical Group NV, formerly known as Tornier NV, is based in Amsterdam, Netherlands.”

More important recent Wright Medical Group Inc (NASDAQ:WMGI) news were published by: Globenewswire.com which released: “Wright Medical Group N.V. Announces Private Placement of $395 Million of 2.25 …” on May 13, 2016, also Benzinga.com published article titled: “Meetings With Wright Medical Management Leave Analysts More Confident Company …”, Benzinga.com published: “Jefferies Says Wright Medical A Top Pick, Management Meetings ‘Heartening'” on August 12, 2016. More interesting news about Wright Medical Group Inc (NASDAQ:WMGI) was released by: Globenewswire.com and their article: “Wright Medical Group N.V. Reports 2016 Second Quarter Financial Results and …” with publication date: August 02, 2016.

WMGI Company Profile

Wright Medical Group N.V., formerly Tornier N.V., is a medical device company. The Firm is focused on extremities and biologics products. The Firm operates through the orthopaedic products segment, which includes the design, manufacture, marketing and sales of extremities, biologics, large joint and other products. The Firm offers a product portfolio of over 160 extremities products and approximately 20 biologics products that are designed to provide solutions to its surgeon customers. The Company’s product portfolio consists of product categories, which include upper extremities, lower extremities, biologics, sports medicine and other, and large joints.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment